Synovial biomarkers in the spondylarthropathies

Current Opinion in Rheumatology

Volumn 18, Issue 4, 2006, Pages 359-363

  Bresnihan, Barry ^a  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

Author keywords

Ankylosing spondylitis; Biomarkers; Psoriatic arthritis; Spondylarthropathies; Synovial tissue

Indexed keywords

BIOLOGICAL MARKER; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; METALLOPROTEINASE; METALLOPROTEINASE INHIBITOR; METHOTREXATE; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

CELL INFILTRATION; CELL POPULATION; DIFFERENTIAL DIAGNOSIS; DRUG EFFECT; DRUG RESPONSE; EARLY DIAGNOSIS; GENOMICS; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOPATHOLOGY; MACROPHAGE; PRIORITY JOURNAL; PROTEOMICS; REVIEW; RHEUMATOID ARTHRITIS; SPONDYLOARTHROPATHY; SYNOVITIS; SYNOVIUM; TREATMENT OUTCOME;

BIOLOGICAL MARKERS; HUMANS; METALLOPROTEASES; METHOTREXATE; SPONDYLARTHRITIS; SYNOVIAL MEMBRANE; TISSUE INHIBITOR OF METALLOPROTEINASES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33748084011     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.bor.0000231903.27419.2d     Document Type: Review

References (27)

1. Healy PJ, Helliwell PS. Classification of the spondylarthropathies. Curr Opin Rheumatol 2005; 17:395-399.
2. Gladman DD, Mease PJ, Krueger G, et al. Outcome measures in psoriatic arthritis. J Rheumatol 2005; 32:2262-2269.
3. Kane D, Gogarty M, O'Leary J, et al. Reduction of synovial sublining layer inflammation and proinflammatory cytokine expression in psoriatic arthritis treated with methotrexate. Arthritis Rheum 2004; 50:3286-3295.
4. Baeten D, Kruithof E, De Rycke L, et al. Infiltration of the synovial membrane with macrophage subsets and polymorphonuclear cells reflects global disease activity in spondylarthropathy. Arthritis Res Ther 2005; 7:R359-R369. Global disease activity in spondylarthropathy correlated significantly with macrophage infiltration, especially the CD163+ subset, and with polymorphonuclear cells.
5. De Gruttola VG, Clax P, DeMets DL, et al. Considerations in the evaluation of surrogate endpoints in clinical trials: summary of a National Institutes of Health workshop. Control Clin Trials 2001; 22:485-502.
6. Haringman JJ, Gerlag DM, Zwinderman AH, et al. Synovial tissue macrophages: a sensitive biomarker for response to treatment in patients with rheumatoid arthritis. Ann Rheum Dis 2005; 64:834-838. Synovial sublining macrophage numbers reflect the clinical response to a range of therapeutic interventions over variable time periods in RA.
7. Veale DJ, Ritchlin C, FitzGerald O. Immunopathology of psoriasis and psoriatic arthritis. Ann Rheum Dis 2005; 64:ii26-ii29.
8. Ritchlin CT. Pathogenesis of psoriatic arthritis. Curr Opin Rheumatol 2005; 17:406-412.
9. Kim T-H, Uhm W-S, Inman RD. Pathogenesis of ankylosing spondylitis and reactive arthritis. Curr Opin Rheumatol 2005; 17:400-405.
10. Kruithof E, Baeten D, De Rycke L, et al. Synovial histopathology of psoriatic arthritis, both oligo- and polyarticular, resembles spondylarthropathy more than it does rheumatoid arthritis. Arthritis Res Ther 2005; 7:R569-R580. The synovial histopathology of PsA resembles that of other spondylarthropathy subtypes, and can be differentiated from RA.
11. Kane D, Jensen LE, Grehan S, et al. Quantitation of metalloproteinase gene expression in rheumatoid and psoriatic arthritis synovial tissue distal and proximal to the cartilage-pannus junction. J Rheumatol 2004; 31:1274-1280.
12. Rihl M, Baeten D, Seta N, et al. Technical validation of cDNA based microarray as screening technique to identify candidate genes in synovial tissue biopsy specimens from patients with spondylarthropathy. Ann Rheum Dis 2004; 63:498-507.
13. Tilleman K, Van Benedon K, Dhondt A, et al. Chronically inflamed synovium from spondylarthropathy and rheumatoid arthritis investigated by protein expression profiling followed by tandem mass spectrometry. Proteomics 2005; 5:2247-2257. The analysis of the cytosolic proteome of synovia l tissue may be a useful approach to identify disease-associated proteins in chronic inflammatory arthritis.
14. Ralph JA, McEvoy AN, Kane D, et al. Modulation of orphan nuclear receptor NURR1 expression by methotrexate in human inflammatory joint disease involves adenosine A2A receptor-mediated responses. J Immunol 2005; 175:555-565.
15. Bresnihan B, Baeten D, Firestein GS, et al. Synovial tissue analysis in clinical trials. J Rheumatol 2005; 32:2481-2484.
16. Montesinos MC, Yap JS, Desai A, et al. Reversal of the antiinflammatory effects of methotrexate by the nonselective adenosine receptor antagonists theophylline and caffeine: evidence that the antiinflammatory effects of methotrexate are mediated via multiple adenosine receptors in rat adjuvant arthritis. Arthritis Rheum 2000; 43:656-663.
17. Kraan MC, Reece RJ, Barg EC, et al. Modulation of inflammation and metalloproteinase expression in synovial tissue by leflunomide and methotrexate in patients with active rheumatoid arthritis: findings in a prospective, randomized, double-blind, parallel-design clinical trial in thirty-nine patients at two centers. Arthritis Rheum 2000; 43:1820-1830.
18. Goedkoop AY, Kraan MC, Teunissen MBM, et al. Early effects of tumour necrosis factor α blockade on skin and synovial tissue in patients with active psoriasis and psoriatic arthritis. Ann Rheum Dis 2004; 63:769-773.
19. Kruithof E, Baeten D, Van den Bosch F, et al. Histological evidence that infliximab treatment leads to downregulation of inflammation and tissue remodeling of the synovial membrane in spondylarthropathy. Ann Rheum Dis 2005; 64:529-536. Infliximab therapy results in profound immunomodulatory changes in synovium of patients with spondylarthropathy.
20. Kruithof E, De Rycke L, Roth J, et al. Immunomodulatory effects of etanercept on peripheral joint synovitis in the spondylarthropathies. Arthritis Rheum 2005; 52:3898-3909. Etanercept effectively downregulates the immunopathologic processes of spondylarthropathy synovitis.
21. De Rycke L, Baeten D, Foell D, et al. Differential expression and response to anti-TNFα treatment of infiltrating versus resident tissue macrophage subsets in autoimmune arthritis. J Pathol 2005; 206:17-27.
22. Kruithof E, De Rycke L, Vandooren B, et al. Identification of synovial biomarkers of response to experimental treatment in early phase clinical trials in spondylarthropathy. Arthritis Rheum (in press).
23. Canete JD, Pablos JL, Sanmarti R, et al. Antiangiogenic effects of anti-tumor necrosis factor a therapy with infliximab in psoriatic arthritis. Arthritis Rheum 2004; 50:1636-1641.
24. Goedkoop AY, Kraan MC, Picavet DI, et al. Deactivation of endothelium and reduction of angiogenesis in psoriatic skin and synoviumby low dose infliximab therapy in combination with stable methotrexate therapy: a prospective single-centre study. Arthritis Res Ther 2004; 6:R326-R334.
25. Vandooren B, Kruithof E, Yu DTY, et al. Involvement of matrix metalloproteinases and their inhibitors in peripheral synovitis and down-regulation by tumor necrosis factor α blockade in spondylarthropathy. Arthritis Rheum 2004; 50:2942-2953.
26. Baeten D, De Keyser F, Mielants H, Veys EM. Immune linkages between inflammatory bowel disease and spondylarthropathies. Curr Opin Rheumatol 2002; 14:342-347.
27. De Rycke L, Vandooren B, Kruithof E, et al. Tumor necrosis factor α blockade treatment down-modulates the increased local and systemic expression of toll-like receptor 2 and toll-like receptor 4 in spondylarthropathy. Arthritis Rheum 2005; 52:2146-2158. Inflammation in spondylarthropathy is characterized by the increased expression of TLR-2 and TLR-4, which is sharply reduced by TNFα blockade.